Clinical Trial Update: Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the safety of a single intravenous dose of recombinant Factor XIII A-subunit in children with congenital Factor XIII deficiency; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Factor Xiii Deficiency

Drugs mentioned

• Recombinant Factor XIII A-subunit (Factor XIII-A subunit)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Congenital FXIII Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2014-06-12